An observational study in Accuracy of Coplanar Template Assisted Seed Implantation for Abdominal and Pelvic Cancer, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-06-18.
Sponsored by Peking University Third Hospital · Observational
In recent years, template guidance has been applied and developed in the field of puncture related operations, such as template-assisted radioactive seed implantation. With the guidance of template, needle pathway of seed implantation, biopsy and fiducial marker implantation can be precisely planned actual operation, which is conducive to the accurate proceeding. Templates can be divided into coplanar templates and non-coplanar templates. The digital coplanar template coordinate puncture system has been developed in China and has been applied in clinical practice.
In previous studies, coplanar template assisted CT-guided radioactive seed implantation has good clinical feasibility for head and neck cancer. However, the accuracy of Coplanar Template Assisted Seed Implantation for Abdominal and Pelvic cancer are lacking in prospective studies. The study aims to prospectively observe the accuracy and safety of Coplanar Template Assisted Seed Implantation for Abdominal and Pelvic cancer.
98 studies on the registry are indexed under Pelvic Neoplasms; 27 are open to participants now.
This study's planned enrollment of 34 is below the median of 184 across 34 observational studies indexed under Pelvic Neoplasms.
Browse Pelvic Neoplasms studies →Peking University Third Hospital is the lead sponsor of 735 studies on the registry; 262 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with Abdominal and Pelvic cancer who are planned to undergo Coplanar Template Assisted Seed Implantation.
Exclusion Criteria:
Dosimetry (D90) between pre-plan and post-plan
Dose covering 90% of target volume between pre-plan and post-plan
Time frame: From the starting to the ending of the seed implantation (generally within 1 week).
Success rate of seed implantation
Success rate of seed implantation
Time frame: From the starting to the ending of the seed implantation (generally within 1 day).
Adverse event
Such as pneumoperitoneum, subcutaneous emphysema, hemorrhage, infection, etc.
Time frame: Acute adverse event is defined as 1 month after seed implantation and beyond 1 month for chronic adverse event.
Operating duration
Operating duration from the starting to the ending
Time frame: From the starting to the ending of the seed implantation (generally within 2 hours)
Local progression-free survival
Local progression-free survival:Duration of the seed implantation to local tumor progression
Time frame: From date of seed implantation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Third Hospital